Mounjaro Philippines: Price and Access

Mounjaro is the trade name Eli Lilly gives to tirzepatide, a dual GIP and GLP-1 receptor agonist administered as a once-weekly subcutaneous injection. The distinction between the brand and the molecule matters more here than it does in most drug categories, because at least four different things circulate in this country under names that sound interchangeable and are not.

Mounjaro is the registered pharmacy product, dispensed against a prescription, in a KwikPen device. Zepboundis Lilly's other tirzepatide brand, marketed for weight management in the markets that carry it, and covered separately in the Zepbound filing. What Philippine pharmacy shelves actually hold is Mounjaro. Research-grade tirzepatide is a lyophilized powder sold in vials for laboratory research, not a registered medicine, and not the same category of product at all. And compounded tirzepatide is what the Philippine College of Endocrinology warned against in August 2025, following similar warnings elsewhere.

People searching "mounjaro philippines price" are almost always asking about the first of those four. That is what the rest of this page answers.

Mounjaro is sold in the Philippines through registered retail pharmacy channels. Watsons Philippines, Southstar Drug and Rose Pharmacy all carry product pages for the KwikPen, and every one of them is flagged prescription required. Watsons routes the product through Click and Collect or in-store pickup rather than ordinary home delivery, and Southstar requires a prescription upload for pharmacist validation before an order is released.

That is the operative fact for a buyer. Mounjaro is not an over-the-counter slimming product and it cannot legitimately be bought as one. A licensed Philippine physician writes the script, a registered pharmacy fills it, and the pen is released against the document. Any seller who skips that step is not offering you a shortcut through paperwork, they are offering you a product outside the chain of custody that makes the paperwork meaningful.

On indication, be precise about what you are asking for. The tirzepatide registration in most markets, including this one, sits with type 2 diabetes first. Weight management indications came later and are handled differently country by country. If your interest is weight rather than glycaemic control, that is a conversation to have openly with a prescriber rather than a detail to leave vague, because it determines whether what you are being prescribed is on-label or off-label for you specifically.

Below is the Watsons Philippines brand listing for Mounjaro, read in August 2026. Because one KwikPen carries four weekly doses, each of these figures is also, near enough, a month of supply at that strength. That makes this table unusually easy to read compared to most pharmacy pricing.

Source: Watsons Philippines Mounjaro listings, read on 26 August 2026. These are listings rather than guaranteed counter prices, they move, and every strength was restricted to click and collect rather than delivery when checked, which is a rationing signal worth reading before you plan a refill.

One Philippine retailer gives you a cross-check. Rose Pharmacy listed the 5mg KwikPen at ₱13,600, within fifty pesos of the Watsons figure, and showed it out of stock at the time. Note the shape of the curve rather than any single number: the jump from 5mg to 7.5mg is roughly ₱6,800, and the 12.5mg and 15mg pens are priced identically, so the highest strength is the best value per milligram in the range and the starter pen is the worst.

For context on where this sits against the rest of the class, the GLP-1 price index tracks the whole shelf, and the Ozempic price filing covers the semaglutide side.

Listed and stocked are different words. All three of the national chains that publish Mounjaro product pages route it through restricted fulfilment, and at least one of them was showing the 5mg pen as available soon rather than in stock at the time of writing, which is retail language for we do not have it.

The hospital pharmacy route is the one most Filipino patients on this drug end up using, and it is worth understanding why. Metro Manila institutional pharmacies such as those at Makati Medical Center, St. Luke's, The Medical City and Asian Hospital hold GLP-1 stock for their own diabetes clinics, which means they restock on a different rhythm than a retail branch and are less likely to be cleared out by walk-in demand. They also tend to price above retail. That premium is real, and in a market where the retail counter is empty it is frequently the difference between filling a script this week and not.

A practical note on how to ask. Do not phone a branch and ask whether they "have Mounjaro". Ask for the specific strength on your script, by milligram, and ask how many pens they hold. A branch with the 2.5mg starter pen and nothing else is a branch that cannot serve you if you are titrated to 7.5mg, and that is the single most common wasted trip in this category.

The supply story for this whole drug class in the Philippines is documented, and the clearest published account is Manila Bulletin's 13 June 2026 report on the semaglutide side. It described Ozempic prices rising from about ₱6,200 to ₱6,300 per pen to the ₱8,734 now listed at major drugstores, with a Las Piñas pharmacy quoted at ₱11,368. A pharmacist described being directed to start rationing, with patients capped at two pens per dosage per month, and one patient described having stock shipped from Mindanao to Metro Manila to fill a prescription.

Mounjaro sits inside the same squeeze from the other side. Demand for tirzepatide has been climbing precisely because semaglutide supply has been unreliable and expensive, which pushes prescribers and patients toward the alternative and thins that shelf in turn. The Manila Bulletin piece noted Mounjaro as an alternative in the market while also observing it was not available in local pharmacies at the time, and it cited a per-unit figure well below the KwikPen listings above, which is a good illustration of why you should treat any single reported Mounjaro number with care and check a real counter.

The demand side is not mysterious. Manila Bulletin cited roughly 4.7 million Filipino adults living with diabetes and around 27 million classified as overweight or obese. A drug class with that addressable population and a global manufacturing bottleneck that started in 2022 was never going to sit quietly on a shelf in Manila. Expect intermittent stockouts to be the normal condition of this market rather than a passing phase, and plan a titration schedule that can survive a missed week.

The device matters for price comparison, so it is worth being exact. Eli Lilly medical information states that each Mounjaro KwikPen contains four doses, one taken weekly, and that the pen delivers a fixed volume of 0.6mL at each dose. That makes one pen a 28-day supply at the labelled strength. It is a multi-dose device with a dial, not a single-shot autoinjector, and a fresh needle goes on for each administration.

Six strengths are sold in the Philippines: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg, all at 0.6mL per dose. The 2.5mg pen exists as a starting strength rather than a maintenance one, which is why it costs nearly as much as the 5mg pen for half the drug. Anyone quoting you a Mounjaro price without naming the strength is quoting you nothing.

One more device point that catches people out. Because a KwikPen is a four-dose pen, a Mounjaro price is not comparable to a single-dose pen price from another brand without doing the arithmetic first. Comparing a KwikPen against one Saxenda pen, for instance, is comparing a month against roughly six days at maintenance dosing. That is covered in the Saxenda filing.

Per-milligram cost is the only way to compare Mounjaro strengths against each other without fooling yourself, so here it is. A KwikPen holds four doses at the labelled strength, so total drug per pen is four times the label.

The curve is not smooth, which is normal for titration pricing. The 2.5mg starter pen is more than twice the cost per milligram of the 15mg pen, and the 5mg and 7.5mg pens sit at effectively the same cost per milligram. None of that is a reason to change a prescribed dose. It is a reason to know what your titration schedule is going to cost you across the whole ramp rather than budgeting from the starter pen.

Set against the rest of the Philippine shelf, a maintenance month of Mounjaro at ₱20,000 to ₱29,900 is at the expensive end of anything you can legally buy here for this purpose. Wegovy runs ₱9,900 to ₱12,650 a pen at Watsons, Ozempic ₱7,650 to ₱8,734, and orlistat a few thousand pesos a month. Those are different molecules with different effect sizes and different labels, so cheaper does not mean equivalent. The full ranking sits in the Ozempic alternatives filing.

The gap between a ₱29,900 pharmacy pen and a marketplace listing at a fraction of that is exactly the gap counterfeiters work in. Facebook groups, Shopee and Lazada reseller pages and Viber sellers are the documented informal channel for GLP-1 pens in this region, and a labelled box tells you nothing about the contents, the batch or the temperature history. The counterfeit GLP-1 filing goes through what has actually been found in this market.

Enforcement is not theoretical either. The NBI arrested two people in Tondo, Manila on 13 May 2026 for selling unregistered tirzepatide online, seizing about ₱310,000 in product, with the case built on RA 9711 section 10(j) alongside RA 10175 and RA 7394. Two weeks later, on 27 May 2026, the NBI and FDA raided an aesthetic clinic in Pasig over unregistered whitening and slimming injectables. Those are the two ends of the same problem: the online seller and the clinic that buys from one.

None of this means the branded pen is the only defensible thing a person can buy. It means that if you have decided you want Mounjaro specifically, the brand is the entire point, and a Mounjaro-labelled product from outside the pharmacy channel gives you neither the brand assurance you are paying for nor the price of the alternatives. It is the worst position on the board.